Eisai slashes full-year guidance on weakness for Aricept and Halaven
00:20 EST 4 Feb 2013 | SCRIP
The main take-away from Eisai's third-quarter results was the major downward revision in sales and profit forecasts for the full fiscal year on much weaker than expected sales of key products Aricept and Halaven. The Japanese.....
Original Article: Eisai slashes full-year guidance on weakness for Aricept and Halaven
More From BioPortfolio on "Eisai slashes full-year guidance on weakness for Aricept and Halaven"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
